Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:MGTA

Magenta Therapeutics (MGTA) Stock Price, News & Analysis

Magenta Therapeutics logo

About Magenta Therapeutics Stock (NASDAQ:MGTA)

Key Stats

Today's Range
$0.68
$0.76
50-Day Range
$0.36
$0.76
52-Week Range
$0.32
$2.07
Volume
376,000 shs
Average Volume
848,835 shs
Market Capitalization
$42.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Magenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation. Its product candidates are designed to bring the curative power of stem cell transplant to patients with blood cancers, genetic diseases, and autoimmune diseases. The company's product portfolio includes MGTA-117, an anti-CD117 antibody conjugated to an amanitin payload that targets hematopoietic stem cells (HSCs) and leukemia cells; and MGTA-45, an anti-human CD45 antibody conjugated to a DNA-interacting payload for HSCs, leukemia cells, and immune cells. In addition, it focus on development of ADC-based conditioning program that targets a receptor of T cells; and novel conditioning and translation stem cell sciences, as well as develops cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. In addition, the company has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. Magenta Therapeutics, Inc. was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Magenta Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
17th Percentile Overall Score

MGTA MarketRank™: 

Magenta Therapeutics scored higher than 17% of companies evaluated by MarketBeat, and ranked 891st out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Magenta Therapeutics.

  • Price to Book Value per Share Ratio

    Magenta Therapeutics has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for MGTA.
  • Dividend Yield

    Magenta Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Magenta Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for MGTA.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Magenta Therapeutics this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Magenta Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    15.18% of the stock of Magenta Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    47.53% of the stock of Magenta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Magenta Therapeutics' insider trading history.
Receive MGTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Magenta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MGTA Stock News Headlines

This Bull Market Indicator called NVDA at $116
Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…
Magenta Buyer LLC Raises $400 Million of New Capital
See More Headlines

MGTA Stock Analysis - Frequently Asked Questions

Magenta Therapeutics, Inc. (NASDAQ:MGTA) issued its quarterly earnings results on Thursday, November, 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.02.

Magenta Therapeutics shares split before market open on Thursday, September 7th 2023. The 2-1 split was announced on Thursday, September 7th 2023. The newly minted shares were payable to shareholders after the closing bell on Thursday, September 7th 2023. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Magenta Therapeutics (MGTA) raised $100 million in an initial public offering on Thursday, June 21st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Magenta Therapeutics investors own include TherapeuticsMD (TXMD), Sorrento Therapeutics (SRNE), NIO (NIO), Outlook Therapeutics (OTLK), VBI Vaccines (VBIV), Corbus Pharmaceuticals (CRBP) and Dynavax Technologies (DVAX).

Company Calendar

Last Earnings
11/04/2021
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:MGTA
Fax
N/A
Employees
67
Year Founded
N/A

Profitability

Net Income
$-76,460,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.23 per share

Miscellaneous

Free Float
51,456,000
Market Cap
$42.44 million
Optionable
Not Optionable
Beta
2.12
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:MGTA) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners